A new study from MSK researchers shows that the combination treatment of radiation plus drug therapy for advanced basal cell #skincancer may control the disease up to 50% longer than radiation alone. Learn more ⬇️bit.ly/3Qqk0Mi

📜 We report the Memorial Sloan Kettering Cancer Center experience of #ablative #radiation for isolated local #recurrence of #pancreas #cancer in JCM MDPI

🙏 Drs Eileen M O’Reilly @Wei_AC Anna Varghese Paul Romesser Christopher H. Crane Marsha Reyngold & those not on X

🔗 mdpi.com/2077-0383/13/9…

New in JCM MDPI Emmanouil Pappou:
Salvage APR for #analcancer SCC for biopsy-proven persistent or recurrent disease after chemoradiation was associated with poor DSS & low RFS. Additional treatment strategies for this high risk group are necessary. #ancsm mdpi.com/2077-0383/13/8…

Dr marisa kollmeier discussing how to design clinical research to focus on the end points that MATTER to patients Memorial Sloan Kettering Cancer Center #radonc Work in Progress meeting.
Example: Fatigue is a HUGE problem for patients & is often underappreciated by providers. #prostateCancer #pcsm

New in Journal of Hematology & Oncology: A combined metabolic tumor volume (on FDG PET/CT) and LDH measure stratified patients with large B-cell lymphoma into high and low PFS risk groups for chimeric antigen receptor T-cell (CAR-T) therapy. #lymsm
🧬jhoonline.biomedcentral.com/articles/10.11…

So proud of the phenomenal work of Drs Trisha Santos, MD, MS and Justin M. Barnes who will present Conquer Cancer, the ASCO Foundation Merit Award winning research in Chicago at #ASCO24 . This next generation of #radonc superstars shows that our future is bright. 🤩🏆🌟

☢️New #radonc #pallonc review Ronald Chow: Superior vena cava (SVC) syndrome occurs due to obstructed blood flow. Mildly hypofrx #radiation regimens are most commonly employed & achieve high rates of symptomatic responses generally within 2 weeks. #hpm
apm.amegroups.org/article/view/1…

Evidence-based guidance on the management of unresectable locally advanced #NSCLC non-small cell #lungcancer scenarios is provided by the American Radium Society Appropriate Use Criteria (AUC) Thoracic Committee to optimize multiD patient care for #lcsm .
🫁jamanetwork.com/journals/jamao…

☢️Dr Chris Barker & Sue Yom in Journal of Clinical Oncology with a Phase II trial for pts with locally advanced, unresectable #basalcellcarcinoma #BCC . This study found combo vismodegib & #radiation ➡️high rates of LRC & PFS with durable improvements in quality of life.
ascopubs.org/doi/10.1200/JC…

☢️Memorial Sloan Kettering Cancer Center skin cancer expert Dr Christopher A. Barker weighs in on a IJROBP - The Red Journal #GrayZone case of a patient with a cT4aN0M0 cutaneous squamous cell carcinoma of the bilateral parietal scalp, which is possibly recurrent after prior treatment.
sciencedirect.com/science/articl…

Proud of my brilliant co-residents — Chris Jackson, MD MS and Trisha Santos, MD, MS — for their ASCO Annual Meeting Merit Awards!

So proud of my friends and colleagues Trisha Santos, MD, MS and Chris Jackson, MD MS for their Conquer Cancer, the ASCO Foundation ASCO awards 🥳🤩🚀

THANK YOU ASCO Conquer Cancer, the ASCO Foundation for your tireless support of trainees and for your continued support of our work to improve cancer care delivery and immigrant health 🤍 shoutout to the best mentors Fumiko Ladd Chino, MD Robin Yabroff for making this all possible 🤍 #ASCO24

Honored to have received this award. It seems like only yesterday I was diagnosed with childhood cancer. To be presenting work on pediatric rhabdomyosarcoma at ASCO is a dream come true. Grateful for the mentorship of Dr. Suzanne Wolden and the Children’s Oncology Group STS team

🏆Big congratulations to Memorial Sloan Kettering Cancer Center #radonc residents Dr Chris Jackson, MD MS (PGY4) and Dr Trisha Santos, MD, MS (PGY5) for their Conquer Cancer, the ASCO Foundation ASCO Annual Meeting Merit Awards for their #ASCO24 abstracts 🙌

💕this Memorial Sloan Kettering Cancer Center trial which optimizes personalized/precision medicine for patients w #lungcancer #lcsm

How do we:
1⃣Customize tx to tumor type
2⃣Catch non-responders EARLY
3⃣Integrate new technologies like #liquid biopsy
4⃣Appropriately CHANGE tx to improve outcomes?

🚨@Oncoalert KRASKickers New Trial Activation!
This study is for pts with #KRAS G12C adeno #NSCLC (~15% #lungcancer ). Goal is to ⬆️outcomes by early use of #liquidbiopsy to identify who is not responding & transition to sotorasib (KRAS G12C inhibitor).
🫁classic.clinicaltrials.gov/ct2/show/NCT06…

Dr Fumiko Ladd Chino, MD is back in DC advocating on key health policy issues that make a difference for patients with cancer. She is representing Memorial Sloan Kettering Cancer Center and ASCO to advocate for legislation which improves access, affordability, and innovation.

Great collaborations between MSK Department of Medicine & Memorial Sloan Kettering Radiation Oncology to show the potential of ePRO to improve accrual for symptom science trials. The quicker we can move science forward. The faster we can change lives for people with cancer!

📜 With Drs @KenrickNg1 @J_Shamash Paul Nguyen, we respond to work by Prof Potosky et al, shedding light on global #QoL among #patients w #prostate #cancer

🙏 JCO Oncology Practice for the invitation to write

🔗 ascopubs.org/doi/10.1200/OP…